{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-038599","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2024-12-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.918687+00:00","generated_at":"2026-05-28T22:33:56.484226+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaxart receives second 180-day Nasdaq extension to cure bid price deficiency until June 30, 2025","bullets":["Nasdaq notified Vaxart on Dec 31, 2024 of an additional 180-day compliance period to meet the $1.00 minimum bid price requirement.","Extension moves the cure deadline from Dec 30, 2024 to June 30, 2025.","Company is considering a reverse stock split as a potential cure for the deficiency.","If not compliant by June 30, 2025, Nasdaq will issue a delisting notice; Vaxart may appeal."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-038599","json":"https://secwatch.observer/filing/0001437749-24-038599.json","markdown":"https://secwatch.observer/filing/0001437749-24-038599.md","text":"https://secwatch.observer/filing/0001437749-24-038599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774924038599/0001437749-24-038599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774924038599/vxrt20241231_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T22:33:56.484226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}